Popular Articles

CytoDyn Completes Safety Testing Of Cytolin(R): Benchmark For Improved Treatment Of HIV/AIDS
CytoDyn, Inc. (Pink Sheets:CYDY) has completed safety testing of its current inventory of Cytolin®, the Company"s immune-system modulator for managing HIV disease and the public health crisis afflicting communities where the infection is spreading due to unprotected sex and the other risk factors for AIDS. Tests for specific adventitious agents and other quality parameters following purification were performed by the manufacturing facility, Vista Biologicals Corporation of Carlsbad, California. The other safety tests, including in vivo general safety using two animal species, were performed by WuXi AppTec, a fully integrated pharmaceutical, biotechnology and medical-device company with facilities in St. Paul, Minnesota. WuXi AppTec provides R&D services to the biotechnology industry. Since the product is intended for use in a clinical trial, the tests conducted were those required for each new batch of a biologic agent manufactured for use in human research. The Company believes that the test results satisfy the current safety standards for the manufacturing of drugs belonging to the class of biologics. The results are summarized in the table below.
generic viagra online
Recent News Reports Of Sweetener Reformulations Raise Questions About Motivations
The misleading "health" halo surrounding highly-publicized marketing campaigns regarding sweetener reformulations is starting to dim.
News of the day
China Quarantines New Orleans Mayor And Wife Over Swine Flu
Although they have no symptoms themselves, the mayor of New Orleans, Louisiana, USA, Ray Nagin, his wife and a member of his security staff
Nutrition

ECRI Institute Calls For Allocating Comparative Effectiveness Funds For A National Patient Library

In testimony before the Listening Panel of the Federal Coordinating Council for Comparative Effectiveness Research (FCCC) on June 10, 2009, ECRI Institute President and Chief Executive Officer Jeffrey C. Lerner, Ph.D., called for devoting a substantial proportion of the $1.1 billion allocated to the comparative effectiveness research to go toward establishing a National Patient Library™. ECRI Institute® (http://www.ecri.org) is an independent nonprofit organization that researches the best approaches to improving patient care. "The ability of patients and their caregivers to compare treatments and not just rely on others to tell them what to do is a powerful way to harness market forces in the service of better care. It allows the public to take statistical information and decide how that information applies to them as individuals," states Lerner. "A national library, rather than a piecemeal collection of studies and initiatives, would create a concrete legacy for the new movement to compare how well pharmaceuticals, medical devices, and clinical procedures work." The National Patient Library would benefit patients by giving them easy-to-understand information about the comparative effectiveness research produced under the American Recovery and Reinvestment Act and from other public and private s. The Library would gather information designed for patients that meets an evidence standard so that patients, their families, and their professional caregivers can make decisions based on the best available scientific information. The Library would also further the way information is developed and presented by bringing to bear knowledge and techniques from behavioral economics, cognitive science, communications, as well as other social sciences. In testifying before the FCCC panel, Dr. Lerner highlighted ECRI Institute"s experience in producing evidence-based patient information beginning in the 1990s when the Institute used it to help breast cancer patients understand that high-dose chemotherapy administered with autologous bone marrow transplant was more likely to harm or kill them than to prolong their lives for a greater period of time than would standard chemotherapy. In 1996, ECRI Institute published a free guide to help patients and their families make an informed decision about whether to undergo this therapy, even though the odds were against it being helpful. In his testimony, Dr. Lerner provided the FCC listening panel with current examples of how evidence-based information has and can continue to be developed to become an important national re and a change agent in the healthcare system. The 15-member FCCC council was created by the American Recovery and Reinvestment Act of 2009 and assists the agencies of the federal government, including the U.S. Department of Health and Human Services and the Departments of Veteran Affairs and Defense, as well as others, to coordinate comparative effectiveness and related health services research . The Recovery Act appropriated $300 million for the Agency for Healthcare Research and Quality, $400 million for the National Institutes of Health, and $400 million for allocation at the discretion of the Secretary of Health and Human Services to support comparative effectiveness research. Council members include Anne Haddix, Thomas Valuck, Peter Delany, Carolyn Clancy, Deborah Parham Hopson, David Hunt, James Scanlon, Elizabeth Nabel, Garth Graham, Jesse Goodman, Michael Marge, Neera Tanden, Joel Kupersmith, Michael Kilpatrick, and Ezekiel Emanuel. Dr. Lerner"s National Patient Library testimony is available for free download (registration required) at http://https://www.ecri.org/Forms/Pages/FCCC_Testimony_National_Patient_Library.aspx. Additional information about ECRI Institute"s vision for a National Patient Library can be found at http://https://www.ecri.org/Patients/Pages/default.aspx. ECRI Institute has also created a Comparative Effectiveness Re Center to help stakeholders understand the issues involved in comparative effectiveness research. The educational site includes a range of res, from national policy conference recordings to perspectives from leading experts, plus links to position statements and related articles. ECRI Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):